Longeveron Says Laromestrocel Missed Phase 2b Endpoint; Stock Falls 59%

What happened

Longeveron Inc. (ticker LGVN) announced topline results from its ELPIS II Phase 2b clinical trial of laromestrocel, a cell-based therapy being tested in infants with hypoplastic left heart syndrome (HLHS), according to a company announcement posted on Longeveron's investor relations site and carried by Yahoo Finance and RTTNews.

The trial did not meet its primary endpoint. Per the company announcement, the endpoint was improvement in right ventricular ejection fraction (RVEF) at month 12. Stock Titan reported that the miss prompted Longeveron to review strategic options and to shift emphasis toward its frailty and longevity programs.

RTTNews reported the stock fell 59% on the news. Price data provided with this story shows Longeveron closed at $2.71, down from a previous close of $6.68, a decline of 59.43%.

Not all measures missed. An X post summarizing the company's announcement stated that the rate of major adverse cardiac events (MACE) was 12 in the treated group versus 19 among controls, a difference described as not statistically significant. That claim comes from a social media post and should be treated accordingly.

What the trial was testing

HLHS is a congenital heart defect in which the left side of the heart is underdeveloped. Infants born with the condition typically require a series of surgeries, and the right side of the heart ends up doing most of the pumping work. RVEF measures how much blood the right ventricle pumps out with each beat — it is a way of quantifying how well that overloaded chamber is functioning.

Laromestrocel is a therapy made from mesenchymal stem cells, a type of cell that can develop into various tissue types and is studied for its potential to reduce inflammation and support tissue repair.

A Phase 2b trial is a mid-stage study, larger than an early safety-focused Phase 1 but smaller than the large Phase 3 trials generally required before a company can seek regulatory approval. It is designed to test whether a treatment shows signs of working, and to help the company decide whether to spend the money a Phase 3 would require.

What this means

In a clinical trial, the primary endpoint is the single pre-specified measure that determines whether the study counts as a success. It is set before the trial begins precisely so that companies cannot pick a favorable measure after the fact. If the primary endpoint is missed, the trial has failed by its own definition, however the other data look.

Secondary endpoints are additional measures tracked in the same study. They can show differences between groups, but they are not the basis on which success or failure was declared, and statistical testing on them is generally considered weaker evidence. That is why a trial can miss its primary endpoint while some secondary measures — like the MACE numbers described in the X post — still appear numerically better in the treated group.

Phase 2b results feed directly into a company's decision about whether to fund a Phase 3 study, which is typically the most expensive phase of development. Longeveron's announcement, as reported by Stock Titan, describes a review of strategic options and a shift toward other programs, which is what companies commonly state when the path forward for a failed program is unclear. The announcement does not explain why the drug failed, and no source provided here offers a cause.

No SEC filing accompanies this event at this time, so there is no regulatory document to cite. The verifiable record consists of the company's own announcement and the news outlets that carried it.